Follow The Filings

PRAX Praxis Precision Medicines

Praxis Precision Medicines earnings company data as of 8:02 PM ET 10/22

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by PRAX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PRAX insider trades
  • None no insider bought on the open market
  • $7.5M sold by 2 insiders outside a trading plan
  • $3.6M sold by 1 insider under 10b5-1 plans
  1. Jill DeSimone Director
    Planned sale
    $3.6M 11,600 shares at $311.32 83% of stake
    Traded Jun 24 Filed Jun 26
  2. Alex Nemiroff General Counsel and Secretary
    Sale
    $4.9M 25,130 shares at $193.09 55% of stake
    Traded Nov 20, 2025 Filed Nov 21, 2025
  3. Lauren Mastrocola Principal Accounting Officer
    Sale
    $2.6M 13,600 shares at $192.08 57% of stake
    Traded Nov 20, 2025 Filed Nov 21, 2025
  4. Adage Capital Management, L.P. 10% owner, +2 joint filers
    Sale
    $33.2M 313,910 shares at $105.76
    Traded Oct 16, 2025 Filed Oct 17, 2025

Also filed in the last 12 months, not counted as buying or selling: 23 stock grants, 14 option exercises, 13 share withholdings for taxes, and 3 gifts.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
8-K 2.02,7.01,9.01
10-Q
8-K 8.01
8-K 4.01,9.01
8-K 8.01
8-K 8.01
8-K 5.07
8-K 8.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
10-Q
8-K 2.02,7.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G —
DEF 14A
DEFA14A
8-K 8.01
8-K 8.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.